Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2008:2:481-6.
doi: 10.4137/cmo.s698. Epub 2008 Jul 18.

Recurrent Respiratory Papillomatosis (RRP)-Juvenile Onset

Affiliations
Case Reports

Recurrent Respiratory Papillomatosis (RRP)-Juvenile Onset

Sara W Dyrstad et al. Clin Med Oncol. 2008.

Abstract

In this article, we describe the treatment of long standing juvenile-onset recurrent respiratory papillomatosis (JORRP) with eventual transformation to carcinoma in a patient who lived to the age of 73. Treatment modalities consisted of bronchoscopy and local excision initially. Later, YAG and CO2 laser debulking were used. Radiotherapy, chemotherapy with carboplatin (300 mg/m2) and 5-FU (600 mg/m2), oral methotrexate (5-7.5 mg/week), pegylated Interferon, indole-3-carbamide, and intralesional cidofovir were also utilized in the treatment of this patient. Except for methotrexate, each of the treatment regimens used in this patient, initially decreased growth of the papillomas and improved symptoms experienced by the patient. Interestingly, we found that this patient's long standing JORRP initially responded to a chemotherapy regimen of 4 cycles of carboplatin (300 mg/m2) and 5-FU (600 mg/m2) as well. Ultimately, the disease became resistant to all forms of treatment and progressed. The patient eventually succumbed to the disease after an approximate 77 year course.

Keywords: cancer; human papilloma virus; respiratory papillomatosis.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Auborn KJ. Therapy for recurrent respiratory papillomatosis. Antivir. Ther. 2002;7(1):1–9. - PubMed
    1. Bonagura VR, Hatam L, DeVoti J, et al. Recurrent respiratory papillomatosis: altered CD8(+) T-cell subsets and T(H)1/T(H)2 cytokine imbalance. Clin. Immunol. 1999;93(3):302–11. - PubMed
    1. DeVoti JA, Steinberg BM, Rosenthal DW, et al. Failure of gamma interferon but not interleukin-10 expression in response to human papillomavirus type 11 E6 protein in respiratory papillomatosis. Clin. Diagn. Lab Immunol. 2004;11(3):538–47. - PMC - PubMed
    1. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367(9518):1247–55. - PubMed
    1. Healy GB, Gelber RD, Trowbridge AL, et al. Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. Results of a multicenter randomized clinical trial. N. Engl. J. Med. 1988;319(7):401–7. - PubMed

Publication types

LinkOut - more resources